We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+49.82%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$434M
AUM Growth
+$81.9M
Cap. Flow
-$31.9M
Cap. Flow %
-7.34%
Top 10 Hldgs %
97.48%
Holding
16
New
1
Increased
–
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$11.7M

Top Sells

Rank Stock Value
1
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$15.4M
2
DGX icon
Quest Diagnostics
DGX
+$9.15M
3
PRGO icon
Perrigo
PRGO
+$9.07M
4
PCRX icon
Pacira BioSciences
PCRX
+$8.74M
5
ABBV icon
AbbVie
ABBV
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 84.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$176M 40.51%
12,850,000
– –
BIIB icon
2
Biogen
BIIB
$30B
$97M 22.35%
310,000
– –
MDCO
3
DELISTED
Medicines Co
MDCO
$66.1M 15.23%
1,752,000
– –
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$29M 6.68%
4,300,000
– –
PCRX icon
5
Pacira BioSciences
PCRX
$1.04B
$14.7M 3.39%
430,000
-223,000
-34% -$8.74M
INVA icon
6
Innoviva
INVA
$1.55B
$11M 2.53%
+1,000,000
New +$11.7M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.3M 2.37%
675,000
– –
AEGR
8
DELISTED
Aegerion Pharmaceuticals
AEGR
$7.87M 1.81%
2,649,000
– –
ADXS
9
DELISTED
Advaxis Inc
ADXS
$6.41M 1.48%
40,000
– –
SEEL
10
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$4.9M 1.13%
13
– –
DGX icon
11
Quest Diagnostics
DGX
$25.7B
$4.23M 0.97%
50,000
-109,000
-69% -$9.15M
VVUS
12
DELISTED
Vivus Inc
VVUS
$2.93M 0.68%
257,394
– –
ABBV icon
13
AbbVie
ABBV
$443B
$2.02M 0.46%
32,000
-18,000
-36% -$1.17M
AVEO
14
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.78M 0.41%
200,000
– –
PRGO icon
15
Perrigo
PRGO
$1.4B
– –
-100,000
Closed -$9.07M
RPTP
16
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-2,875,000
Closed -$15.4M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sarissa Capital Management held 16 positions worth $434M, up 23% from $352M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Sarissa Capital Management withdrew a net $31.9M in Q3 2016, closing 2 positions and reducing 3 holdings. Its most notable exit was RAPTOR PHARMACEUTICAL CORP COM STK (DE), an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier.

Against the trend, Sarissa Capital Management opened a new position in Innoviva worth $11M.

  • Sarissa Capital Management's largest Q3 2016 buy was Innoviva: 1,000,000 shares worth $11M.
  • Sarissa Capital Management's biggest Q3 2016 reduction was Quest Diagnostics, cutting an estimated $9.15M.
  • Sarissa Capital Management fully exited RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q3 2016, selling an estimated $15.4M.
  • Sarissa Capital Management's ten largest holdings make up 97% of its $434M portfolio in Q3 2016.
  • Sarissa Capital Management opened 1 new position and closed 2 in Q3 2016.
  • Sarissa Capital Management's portfolio value rose 23% quarter-over-quarter to $434M.

Based on Sarissa Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.